Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma

Radioiodine (RAI) is the mainstay of treatment for differentiated thyroid carcinoma (DTC) following total thyroidectomy. Nevertheless, about 5% of patients with DTC are RAI-refractory (RAI-R). Understanding the molecular mechanisms associated with DTC during progression towards RAI-R DTC, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Samimi, Hilda, Haghpanah, Vahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812241/
https://www.ncbi.nlm.nih.gov/pubmed/35114985
http://dx.doi.org/10.1186/s12935-022-02484-3
_version_ 1784644607563268096
author Samimi, Hilda
Haghpanah, Vahid
author_facet Samimi, Hilda
Haghpanah, Vahid
author_sort Samimi, Hilda
collection PubMed
description Radioiodine (RAI) is the mainstay of treatment for differentiated thyroid carcinoma (DTC) following total thyroidectomy. Nevertheless, about 5% of patients with DTC are RAI-refractory (RAI-R). Understanding the molecular mechanisms associated with DTC during progression towards RAI-R DTC, including thyroid-stimulating hormone levels, may help to explain the pathophysiology of challenging RAI-R DTC clinical cases. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-8812241
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88122412022-02-07 Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma Samimi, Hilda Haghpanah, Vahid Cancer Cell Int Hypothesis Radioiodine (RAI) is the mainstay of treatment for differentiated thyroid carcinoma (DTC) following total thyroidectomy. Nevertheless, about 5% of patients with DTC are RAI-refractory (RAI-R). Understanding the molecular mechanisms associated with DTC during progression towards RAI-R DTC, including thyroid-stimulating hormone levels, may help to explain the pathophysiology of challenging RAI-R DTC clinical cases. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2022-02-03 /pmc/articles/PMC8812241/ /pubmed/35114985 http://dx.doi.org/10.1186/s12935-022-02484-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Hypothesis
Samimi, Hilda
Haghpanah, Vahid
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
title Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
title_full Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
title_fullStr Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
title_full_unstemmed Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
title_short Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
title_sort molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
topic Hypothesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812241/
https://www.ncbi.nlm.nih.gov/pubmed/35114985
http://dx.doi.org/10.1186/s12935-022-02484-3
work_keys_str_mv AT samimihilda molecularevidencerevealsthyrotropininterventionenhancestheriskofdevelopingradioiodinerefractorydifferentiatedthyroidcarcinoma
AT haghpanahvahid molecularevidencerevealsthyrotropininterventionenhancestheriskofdevelopingradioiodinerefractorydifferentiatedthyroidcarcinoma

Ejemplares similares